Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694112 | 0.87 | NPC1 (0.49) | RAB9ANPC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL30536136 | 0.82 | BRD4 (0.63) | RAB9ANPC1TP53 | |
| SCHEMBL6933558 | 0.82 | BRD4 (0.63) | RAB9ANPC1TP53 | |
| SCHEMBL5694204 | 0.79 | BRD4 (0.66) | XDHTMIGD3HTR2CHTR2BSTAT3 | |
| SCHEMBL1970070 | 0.77 | GDA (0.58) | RAB9ANPC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5694220 | 0.74 | XDH (0.65) | XDHTMIGD3HTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL5194370 | 0.73 | XDH (0.53) | XDHTMIGD3HTR2CHTR2BNPC1 | |
| SCHEMBL25921184 | 0.71 | GAA (0.56) | RAB9ANPC1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL7148662 | 0.71 | XDH (0.50) | XDHTMIGD3HTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL6016640 | 0.71 | XDH (0.50) | XDHTMIGD3HTR2CHTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | XDH 998/4885TMIGD3 4662/4885HTR2C 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.